Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oncosec will be presenting preliminary PISCES data at upcoming ASCO conference:
Abstract TPS9601
Trial in progress: A phase 2 study of intratumor pil-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV mealanoma progressing on either pembrolizumab or nivolumab treatment (PISCES).
Robert Hans Ingemar Andtbacka, MD - First Author
Huntsman Cancer Institute at the University of Utah
https://iplanner.asco.org/am2018/#/
BMY Bulls are throwing in the towel and finally shifting back to Merck. Merck is about to continue on it's longer-term uptrend from the market bottom of 2009. I predict sometime in the near future Merck will get their shot at retesting all-time highs going back 20 years ago. Keytruda will be the main growth driver going forward. The Animal Health division is looking very good. Merck could always surprise the market and do a Pfizer-like (Zoetis) spinoff to create shareholder value. Lots to like in Merck stock right now.
When PISCES data is released, Merck will have the validation they are waiting for with Oncosec. Positive data will give them the green light to either expand their collaboration with Oncosec to other indications, a licensing deal in melanoma or a flat out buyout deal. If it happens it happens, all depends on PISCES data. Nobody will know until later this year. If the data is good I think the stock price will be much higher. In the meantime the market seems a little worried and the price has declined. Hopefully we hear about TNBC partnering to stop the bleeding. Tomorrow is Rocky Mountain Bio Conference and Oncosec will present. Maybe we see a bounce tomorrow.
Merck regaining market confidence at AACR. NIce to see Keytruda rocking the house again.
From this statement in the abstract I believe Oncosec will have more than 5 patient data to report. More than 2 patients treated with Opdivo after ep-il12 will be a major plus if we see a few more responders to combo therapy. Since the abstract submission they would have had enough time to dose a few more patients in my opinion.
"At the time of abstract submission, 5 patients have completed all study-related procedures ... Two patients with treatment refractory TNBC received nivolumab ... and experienced clinically meaningful objective responses. Updated data will be presented."
Sunday Oncosec will reveal plans for the phase II TNBC trial. Phase 1 showed enough evidence to warrant a combination phase II trial. What will be interesting is if BMY will be partneing either for drug supply or with upfront cash. Either way, Oncosec has already secured 23 million from the last equity offering to sponsor the trial themselves.
Looking forward to hearing the webcast when it is posted. Monday will be very interesting indeed. Good luck to all Oncosec shareholders.
Nice action after hours in Oncosec. From what we know so far from the TNBC abstract is that epIL-12 is boosting Til density.....and hopefully jumpstarting a response to Opdivo. The 2 patients that were administered Opdivo after epIL12 had "experienced clinically meaningful objective responses". We will have to wait for Sunday for detailed information on the data. The 2 patients were refractory to prior treatments (chemo, but no mention if they previously failed keytruda or Opdivo).
No that is probably the train you are on going in the wrong direction....still not too late to get on the right train though.
Yup...it is definitely Oncosec's year to shine....and shareholders who see the light at the end of the tunnel....we are closing in now.
okay....your loss....come monday we are at $3.
okay but come monday you could be up 50% when we hit $3.
ok...hey look...ONCS just went green....you still have a chance to grab some shares. End of day run coming.
Ok...talk to you about it on monday morning. You still have time to buy shares at this discounted price before the weekend.
Yup!....$3 on monday.
I am thinking a gap up to recent highs from November after SITC data....closer to the $3 level....not simply a fraction of a penny.
Monday morning Oncosec will gap up on Bristol Myers partnering news for TNBC phase II trial. We will discuss this outcome then. If I am wrong you can tell me then.
Which is exactly what your opinion is based on as well...LOL. Oncosec remains as a solid investment opportunity this year....and that opinion has my strongest conviction ....and I stand by it.
Expecting real news from AACR Sunday on Oncosec's pipeline and partnering prospects.....and not fake news as some would have investors believe.
let's talk about it monday morning....AACR will provide more information by which to base a more accurate analysis of the current trading situation.
nope....major gap up monday morning after AACR. Short traders are leaving yes, smart investors holding strong.
This time it is for real, that is why Oncosec was granted fast track designation by the FDA. Oncosec only needs to post a 30% response (BORR) rate to be considered a success. Onwards and upwards.
It is very easy to predict a stock will fall when it posts nice gains.....short-term profit takers come in until there is definitive news that supports a stock at higher prices. AACR and the release of PISCES news will give Oncosec much needed support at higher prices.....and short traders will be chasing it again.
trials take a long time and when Oncosec changed the protocol of the first Merck combo trial to include non-responders to anti-pd1....they did so knowing that it would be the fastest route to an approval which will likely be within 1 year now. That means that with a positive review from the FDA...Oncosec is likely going to get buyout interest. This weekend we may hear news about Bristol Myers interest in TNBC combo with Oncosec also.
If it does get approved it is certainly worth more than $1.80 per share. At the very least 500 mil market cap and $10 share price is coming
It has been greatly improved over the years and on the brink of an FDA approval....I call that great science.
Oncosec has strong science, I truly think it will work out.
It does look like an up and down heartbeat. We are trading in a channel and I think Sunday should give us some news hopefully to break us out of this channel towards $3 and prime the share price for PISCES data later this year.
smart people know fake news from real news and worthy information. Oncosec is going to be a winner plain and simple to those smart enough to see the real science here. Even a partnering deal with big pharma when it happens will not satisfy some opinions on Oncosec...to each his own.
luckily it will be webcast so no need to show up at the actual event. News is news no matter where you are when you hear it. I am looking forward to the updates and possible BMY partnering news for TNBC phase II trial.
way too negative with that number.
Maybe not manipulation...but maybe short term profit taking. Sunday news will be important and has the potential to move the stock higher before we get PISCES data this year.
The Research Reception sunday at AACR has alot to look forward to. Price monday morning will hopefully reflect this.
The OncoSec Research Reception will feature the following presentations:
OMS-140 Protocol; Review of Intratumoral IL-12 Data in TNBC Presented at AACR
Pamela Munster, MD, UCSF Helen Diller Family Comprehensive Cancer Center
OMS-141 Protocol; Upcoming PD-1 Combination Clinical Trial in TNBC
Melinda Telli, MD, Stanford University Medical Center
Melanoma Data Update: OMS-100 & OMS-102 Combination Study
Alain Algazi, MD, UCSF Helen Diller Family Comprehensive Cancer Center
PISCES/KEYNOTE-695 Operational Update
Sharron Gargosky, PhD, Chief Clinical and Regulatory Officer, OncoSec
Yesterdays price action in Oncosec was obviously manipulation. The friday S-8 is obviously stock options at 2.13 above current stock price. People paniced and sold.
Don't worry, PISCES data should clear that up for you.
How many of those other trials are on the brink of a fast track fda approval in melanoma?...not many I would bet, unlike Oncosec
Incyte/Merck epicodistat combo just failed big. Next hope for Merck will be Oncosec... Tutes piling in ONCS now see the market hopes shifting our way.
The fact that the Oncosec message board is so active tells me Oncosec is definitely going much higher.
I would expect another late day run like the last few days to break us through $2 again. Definitely loading happening here.
Oncosec continues to build momentum. Looks like we may hit 2.00 after hours. AACR is closing in and TNBC is in the spotlight right now. Oncosec might not be ready to present interim data yet for PISCES....hoping for ASCO but that might be too soon...thinking SITC again in November might be when we get PISCES data for first cohort of patients. Better not to rush the data and wait til the fall in my opinion.